You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

687 Results
Document
Jan 2024
Document
Jan 2024
Document
Feb 2024
Document
Feb 2024
Regimen
Cancer Type:
Hematologic, 
Leukemia - Chronic Lymphocytic (CLL)
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    zanubrutinib - For the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) who have received at least one prior therapy; and for the treatment of adult patients with previously untreated CLL.
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
zanubrutinib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Mar 2024
Document
Feb 2024
Document
Feb 2024
Drug
Other Name(s): Brukinsa®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Apr 2024
Document
Mar 2024
Document
Apr 2024
Document
Apr 2024
Document
Apr 2024

Pages